Cognition Therapeutics (NASDAQ:CGTX) Announces Earnings Results

Cognition Therapeutics (NASDAQ:CGTX) released its earnings results on Thursday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01), Zacks reports. During the same quarter in the previous year, the company earned ($0.27) EPS.

Cognition Therapeutics Stock Performance

NASDAQ:CGTX opened at $0.45 on Friday. The company has a market capitalization of $18.90 million, a PE ratio of -0.47 and a beta of 1.03. The company has a 50 day simple moving average of $0.58 and a two-hundred day simple moving average of $0.55. Cognition Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.95.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Chardan Capital decreased their price target on Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday. HC Wainwright lifted their price target on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday, December 19th. Finally, Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $7.70.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.